---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-24-000009"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T07:51:56.214587+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Novavax Q4 revenue $291M, full-year net loss $545M; guides 2024 revenue $800M-$1B

## Summary
- Q4 2023 revenue $291M (down 18% YoY); full-year revenue $984M (down 51% from $2B in 2022).
- Full-year 2023 net loss $545M vs $658M in 2022; operating expenses cut 41% ($1.1B reduction).
- Cash $584M at Dec 31, 2023, down from $1.3B a year earlier; raised $110M via ATM offerings in Q4.
- FY2024 guidance: total revenue $800M-$1B, combined R&D+SG&A $700-$800M; Q1 2024 revenue expected ~$100M.
- Announced Gavi settlement; plan to start Phase 3 COVID-flu combo trial in H2 2024 with potential 2026 launch.

## SEC filing metadata
- accession: 0001000694-24-000009
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/0001000694-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/nvax-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-24-000009
- JSON: https://secwatch.observer/filing/0001000694-24-000009.json
- Plain text: https://secwatch.observer/filing/0001000694-24-000009.txt

## Key facts
- Earnings Releases
  NOVAVAX INC updated its the fourth quarter and twelve months ended December 31, 2023 guidance (reaffirmed).
  - Period: the fourth quarter and twelve months ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 28, 2024, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/0001000694-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.